DK3723752T3 - Nye fast former for cannabidiol og anvendelse heraf - Google Patents

Nye fast former for cannabidiol og anvendelse heraf Download PDF

Info

Publication number
DK3723752T3
DK3723752T3 DK18887462.2T DK18887462T DK3723752T3 DK 3723752 T3 DK3723752 T3 DK 3723752T3 DK 18887462 T DK18887462 T DK 18887462T DK 3723752 T3 DK3723752 T3 DK 3723752T3
Authority
DK
Denmark
Prior art keywords
cannabidiol
solid forms
new solid
new
forms
Prior art date
Application number
DK18887462.2T
Other languages
English (en)
Inventor
R Martin Emanuele
Tanise Shattock-Gordon
Tabitha Williford
Mark Andres
Patricia Andres
Original Assignee
Artelo Biosciences Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Artelo Biosciences Inc filed Critical Artelo Biosciences Inc
Application granted granted Critical
Publication of DK3723752T3 publication Critical patent/DK3723752T3/da

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C39/00Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring
    • C07C39/23Compounds having at least one hydroxy or O-metal group bound to a carbon atom of a six-membered aromatic ring polycyclic, containing six-membered aromatic rings and other rings, with unsaturation outside the aromatic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/045Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05Phenols
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/658Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A61K47/183Amino acids, e.g. glycine, EDTA or aspartame
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/545Heterocyclic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/14Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D207/00Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D207/02Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D207/04Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
    • C07D207/10Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D207/16Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D241/00Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings
    • C07D241/02Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings
    • C07D241/10Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members
    • C07D241/12Heterocyclic compounds containing 1,4-diazine or hydrogenated 1,4-diazine rings not condensed with other rings having three double bonds between ring members or between ring members and non-ring members with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to ring carbon atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07BGENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13Crystalline forms, e.g. polymorphs
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07CACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00Systems containing only non-condensed rings
    • C07C2601/12Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Pyrrole Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pyridine Compounds (AREA)
DK18887462.2T 2017-12-11 2018-12-10 Nye fast former for cannabidiol og anvendelse heraf DK3723752T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201762597307P 2017-12-11 2017-12-11
PCT/US2018/064773 WO2019118360A1 (en) 2017-12-11 2018-12-10 New solid forms of cannabidiol and uses thereof

Publications (1)

Publication Number Publication Date
DK3723752T3 true DK3723752T3 (da) 2024-11-04

Family

ID=66735157

Family Applications (1)

Application Number Title Priority Date Filing Date
DK18887462.2T DK3723752T3 (da) 2017-12-11 2018-12-10 Nye fast former for cannabidiol og anvendelse heraf

Country Status (15)

Country Link
US (4) US20190177258A1 (da)
EP (1) EP3723752B1 (da)
JP (1) JP7429013B2 (da)
KR (1) KR102898087B1 (da)
CN (1) CN111447929B (da)
AU (1) AU2018383598B2 (da)
BR (1) BR112020011625A2 (da)
CA (1) CA3085331A1 (da)
DK (1) DK3723752T3 (da)
ES (1) ES2992415T3 (da)
FI (1) FI3723752T3 (da)
MX (1) MX2020006071A (da)
PT (1) PT3723752T (da)
TW (1) TWI794361B (da)
WO (1) WO2019118360A1 (da)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3665145A1 (en) * 2017-08-07 2020-06-17 Enantia, S.L. A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol
WO2019084292A1 (en) * 2017-10-25 2019-05-02 Arizona Board Of Regents On Behalf Of The University Of Arizona COMPOSITIONS AND METHODS FOR ADMINISTERING PHARMACEUTICAL AGENTS
WO2020089424A1 (en) * 2018-10-31 2020-05-07 Enantia, S.L. Solid compositions of cocrystals of cannabinoids
GB201912760D0 (en) * 2019-09-05 2019-10-23 Healx Ltd Treatment
US20220332682A1 (en) * 2019-09-06 2022-10-20 Ebers Tech Inc. Caanabigerol proline cocrystals
US20230381134A1 (en) * 2020-01-03 2023-11-30 Purisys, Llc Cocrystals of cannabinoids
US10981849B1 (en) * 2020-02-20 2021-04-20 Sci Pharmtech Inc. Method for preparing cannabinoids
WO2021234449A1 (en) * 2020-05-19 2021-11-25 Ebers Tech Inc. Tetrahydrococannabinolic acid cocrystals
CN111882044B (zh) * 2020-08-05 2021-09-14 四川大学 一种基于图神经网络的共晶预测方法、深度学习框架
US11672761B2 (en) 2020-11-16 2023-06-13 Orcosa Inc. Rapidly infusing platform and compositions for therapeutic treatment in humans
WO2022103638A1 (en) 2020-11-16 2022-05-19 Orcosa Inc. Cannabinoids in the treatment of autism spectrum disorder
CN114177163B (zh) * 2022-01-12 2023-05-02 刘树民 一种治疗高血压的药物
WO2025122802A1 (en) * 2023-12-05 2025-06-12 Artelo Biosciences, Inc. Increased bioavailability and efficacy of cbd via coadministration with tetramethylpyrazine
US20250236581A1 (en) 2024-01-23 2025-07-24 Manoira Corporation Cannabidiolic acid cocrystals

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4859674A (en) 1987-06-12 1989-08-22 Houston Biotechnology Incorporated Pyrazine in prevention and treatment of strokes
EP1482917B1 (en) 2002-02-01 2019-05-08 GW Pharma Limited Compositions comprising cannabidiolic acid for treatment of nausea, vomiting, emesis, motion sickness or like conditions
GB2393182B (en) * 2002-09-23 2007-03-14 Gw Pharma Ltd Method of preparing cannabidiol from plant material
JP5069905B2 (ja) * 2003-01-21 2012-11-07 アプテュイト (ウエスト ラファイエット)、エルエルシー 新規な共結晶化
ATE550022T1 (de) * 2003-02-28 2012-04-15 Mcneil Ppc Inc Pharmazeutische mischkristalle von celecoxib- nicotinamid
US7091205B2 (en) 2004-10-08 2006-08-15 Yu Show Fu Use of tetramethylpyrazine in the treatment of brain tumor
US8088773B2 (en) 2005-05-12 2012-01-03 The Texas A&M University System Therapeutic compositions and methods
TWI370818B (en) * 2006-04-05 2012-08-21 Astellas Pharma Inc Cocrystal of c-glycoside derivative and l-proline
EP2249837A4 (en) * 2008-01-31 2011-06-15 Univ Monash METHOD FOR TREATING THROMBOEMBOLIC ILLNESSES
EP2123626A1 (en) * 2008-05-21 2009-11-25 Laboratorios del Dr. Esteve S.A. Co-crystals of duloxetine and co-crystal formers for the treatment of pain
MX2011011445A (es) * 2009-04-29 2011-11-18 Univ Kentucky Res Found Composiciones que contienen cannabinoides y metodos para su uso.
US8576985B2 (en) 2009-09-01 2013-11-05 Aptuit (West Lafayette) Llc Methods for indexing solid forms of compounds
US20110200531A1 (en) 2009-09-14 2011-08-18 The Regents Of The University Of California Treatment and diagnosis of central nervous system disorders
BR112012007364A2 (pt) * 2009-10-23 2017-06-06 Astellas Pharma Inc composição farmacêutica para administração oral
WO2012116349A2 (en) * 2011-02-26 2012-08-30 Amplio Pharma, Llc Novel cocrystals of ezetimibe
WO2013040419A1 (en) * 2011-09-14 2013-03-21 The Trustees Of Columbia University In The City Of New York Compositions and methods for treating hyperprolinemia-associated mental disorders
US9822384B2 (en) 2014-07-14 2017-11-21 Librede Inc. Production of cannabinoids in yeast
AU2016215094B2 (en) 2015-02-05 2019-09-26 Colorado Can Llc Purified CBD and CBDA, and methods, compositions and products employing CBD or CBDA
US10399920B2 (en) * 2016-06-01 2019-09-03 S&B Pharma, Inc. Crystalline form of cannabidiol
EP3665145A1 (en) * 2017-08-07 2020-06-17 Enantia, S.L. A cocrystal of 2-[(1r,6r)-6-isopropenyl-3-methylcyclohex-2-en-1-yl]-5-pentylbenzene-1,3-diol

Also Published As

Publication number Publication date
KR102898087B1 (ko) 2025-12-09
US20230404939A1 (en) 2023-12-21
CN111447929A (zh) 2020-07-24
JP7429013B2 (ja) 2024-02-07
US11364202B2 (en) 2022-06-21
ES2992415T3 (es) 2024-12-12
US20210299048A1 (en) 2021-09-30
EP3723752A1 (en) 2020-10-21
WO2019118360A1 (en) 2019-06-20
JP2021505674A (ja) 2021-02-18
CA3085331A1 (en) 2019-06-20
MX2020006071A (es) 2020-10-28
TW201927733A (zh) 2019-07-16
CN111447929B (zh) 2024-05-31
US20190177258A1 (en) 2019-06-13
BR112020011625A2 (pt) 2020-11-17
PT3723752T (pt) 2024-11-07
TWI794361B (zh) 2023-03-01
EP3723752B1 (en) 2024-08-21
US20190300466A1 (en) 2019-10-03
FI3723752T3 (fi) 2024-11-13
EP3723752A4 (en) 2021-10-20
US10604467B2 (en) 2020-03-31
KR20200097285A (ko) 2020-08-18
AU2018383598B2 (en) 2024-03-07
AU2018383598A1 (en) 2020-06-18

Similar Documents

Publication Publication Date Title
DK3723752T3 (da) Nye fast former for cannabidiol og anvendelse heraf
IL293377B1 (en) Hsd17b13 variants and uses thereof
DK3615527T3 (da) Nye azaquinolin-derivater
HUE052373T2 (hu) Szubsztituált krománok és alkalmazási eljárások
PL3481852T3 (pl) Nowa neurotoksyna botulinowa i jej pochodne
EP3526222A4 (en) TYK2 INHIBITORS AND THEIR USES
EP3528816A4 (en) TYK2 INHIBITORS AND USES THEREOF
PL4393545T3 (pl) Nowe zastosowania pochodnych piperydynylo-indolowych
DK3497117T5 (da) Nye alkalisk stabile immunglobulin-bindende proteiner
IL253463A0 (en) Binding-triggered transcriptional switches and methods of use thereof
DK3486242T3 (da) Oxopicolinamidderivat, fremgangsmåde til fremstilling deraf og farmaceutisk anvendelse deraf
DK3555076T3 (da) Nye phenylpropionsyrederivater og anvendelser deraf
DK3565806T3 (da) Nye phenylderivater
DK3368014T3 (da) Nye formuleringer af cannabinoider
DK3365339T3 (da) Nye ferroportin-hæmmere
EP3478308A4 (en) CANNABIS-BASED COMPOSITION AND PROCESSES
DK3452463T3 (da) Amidsubstituerede pyridinyltriazolderivater og anvendelser deraf
PL3167096T3 (pl) Dwuetapowy sposób nanoszenia
DK3160966T3 (da) Mnk-inhibitorer og fremgangsmåder forbundet dermed
DK3509591T3 (da) Nye jak1-selektive inhibitorer og anvendelser deraf
DK3288553T3 (da) Kombinationer af cannabinoider og n-acylethanolaminer
GEAP201914237A (en) Heteroaryls and uses thereof
PL3676027T3 (pl) Sposób klasyfikacji i urządzenie
DK3443010T3 (da) Nye anti-SIRPa-antistoffer og terapeutiske anvendelser deraf
DK3233111T3 (da) Farmaceutisk sammensætning, der omfatter plasminogen, og anvendelser deraf